{
  "ticker": "LLY",
  "target_date": "2025-06-23",
  "actual_date": "2025-06-23",
  "collected_at": "2025-12-08T11:55:33.127484",
  "price": {
    "open": 767.71,
    "high": 790.31,
    "low": 761.04,
    "close": 767.8234252929688,
    "volume": 3951500,
    "change_1d_pct": 1.04,
    "change_7d_pct": -4.7,
    "change_30d_pct": 2.76
  },
  "technicals": {
    "rsi_14": 58.58,
    "sma_20": 764.99,
    "sma_50": 774.42,
    "macd": 5.454,
    "macd_signal": 4.883,
    "macd_histogram": 0.571,
    "bb_upper": 831.39,
    "bb_lower": 698.6,
    "price_vs_sma20_pct": 0.37,
    "price_vs_sma50_pct": -0.85,
    "volume_ratio": 1.19
  },
  "fundamentals": {
    "market_cap": 892524625920,
    "pe_ratio": 48.78068,
    "forward_pe": 43.937057,
    "price_to_book": 37.48546,
    "price_to_sales": 15.02066,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.47,
    "pct_from_52w_low": 59.61
  },
  "macro": {
    "spy": {
      "price": 598.49,
      "change_1d_pct": 0.99,
      "change_7d_pct": -0.3
    },
    "vix": {
      "level": 19.83,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.32
    },
    "dollar_index": {
      "level": 98.42
    },
    "gold": {
      "price": 3377.7
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "Eli Lilly (LLY) Surpasses Market Returns: Some Facts Worth Knowing",
      "source": "Yahoo",
      "datetime": 1750715103,
      "summary": "The latest trading day saw Eli Lilly (LLY) settling at $770.64, representing a +1.04% change from its previous close.",
      "url": "https://finnhub.io/api/news?id=fe54652e01f7144501b883b0d704b46ae91ae1c10072f93eae48d1c63fbb21cd"
    },
    {
      "headline": "Amgen Shares Fall on Weight-Loss Drug Tummy Troubles",
      "source": "Yahoo",
      "datetime": 1750709700,
      "summary": "At the highest dosage of MariTide, 27% of patients stopped the drug due to a gastrointestinal adverse event.",
      "url": "https://finnhub.io/api/news?id=9a1532c9b7acdd1fddda703e9cdca95baa0515f6dc3cd918b96c24a031a5f8c1"
    },
    {
      "headline": "Amgen Hammered As 'Tough' Obesity Meeting Reminds It It's Not The Incumbent",
      "source": "DowJones",
      "datetime": 1750706210,
      "summary": "Amgen Hammered As 'Tough' Obesity Meeting Reminds It It's Not The Incumbent",
      "url": "https://finnhub.io/api/news?id=f25d8a2b9e288fb49d127c8391a9611c43c3daf14d4ba9b131e6a25874402f6d"
    },
    {
      "headline": "HIMS Stock Crashes 30% in a Day: Time to Buy the Dip?",
      "source": "Yahoo",
      "datetime": 1750704600,
      "summary": "Hims & Hers stock crashes 30% on Monday after news of Novo Nordisk ending their partnership. Is HIMS now a compelling stock to buy?",
      "url": "https://finnhub.io/api/news?id=a725160509dd8d691c83b6e1599c8673e410d03163cd721b6c7b73a66c2bd462"
    },
    {
      "headline": "Amgen gears up for phase 3 trial of monthly weight-loss drug MariTide amid mixed investor sentiment",
      "source": "Yahoo",
      "datetime": 1750703415,
      "summary": "Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its phase 3 trial.",
      "url": "https://finnhub.io/api/news?id=731535931fe6e0fad4df2a157e1e3b4e0556bad018d45fa3cb2bdac0b20606ee"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750199300.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000176/xslF345X05/wk-form4_1750199300.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750199159.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000174/xslF345X05/wk-form4_1750199159.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750198988.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000172/xslF345X05/wk-form4_1750198988.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750198711.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000170/xslF345X05/wk-form4_1750198711.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750198504.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000168/xslF345X05/wk-form4_1750198504.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}